NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free CNTA Stock Alerts $11.30 +0.20 (+1.80%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.82▼$11.4750-Day Range$7.46▼$12.2052-Week Range$3.52▼$12.45Volume172,356 shsAverage Volume406,665 shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Centessa Pharmaceuticals alerts: Email Address Centessa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside11.5% Downside$10.00 Price TargetShort InterestHealthy2.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 13 Articles This WeekInsider TradingSelling Shares$642,344 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.63) to ($1.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.64 out of 5 starsMedical Sector874th out of 938 stocksPharmaceutical Preparations Industry386th out of 417 stocks 1.4 Analyst's Opinion Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Centessa Pharmaceuticals has a forecasted downside of 11.5% from its current price of $11.30.Amount of Analyst CoverageCentessa Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.76% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTA. Previous Next 2.5 News and Social Media Coverage News SentimentCentessa Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Centessa Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CNTA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows14 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $642,344.00 in company stock.Percentage Held by Insiders11.54% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to decrease in the coming year, from ($1.63) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.Read More CNTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNTA Stock News HeadlinesMarch 27, 2024 | insidertrades.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 51,160 Shares of StockMarch 29, 2024 | msn.comCNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | finanznachrichten.deCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023March 28, 2024 | finance.yahoo.comCentessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 ResultsMarch 28, 2024 | globenewswire.comCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023March 27, 2024 | finance.yahoo.comCentessa Pharmaceuticals PLC Chief People Officer Sells Company SharesMarch 27, 2024 | americanbankingnews.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 51,160 Shares of StockMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | finance.yahoo.com7 Biotech Stocks Ready to Ride the Sector’s ResurgenceMarch 23, 2024 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month High at $12.41March 20, 2024 | wsj.comCentessa Pharmaceuticals PLC ADRMarch 19, 2024 | investing.comCentessa Pharmaceuticals PLC ADR (CNTA)March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comCNTA Apr 2024 7.500 putMarch 16, 2024 | finance.yahoo.comCNTA Apr 2024 5.000 callMarch 16, 2024 | finance.yahoo.comCNTA Jul 2024 7.500 putMarch 12, 2024 | finance.yahoo.comPrivate equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139mMarch 7, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Centessa Pharmaceuticals on SerpinPC’s Market PotentialFebruary 22, 2024 | finance.yahoo.comCentessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceFebruary 15, 2024 | seekingalpha.comCNTA Centessa Pharmaceuticals plcFebruary 14, 2024 | benzinga.comCentessa Pharmaceuticals Stock (NASDAQ:CNTA) Dividends: History, Yield and DatesFebruary 10, 2024 | markets.businessinsider.comCentessa Pharmaceuticals Unveils Clinical Data OnlineFebruary 9, 2024 | finance.yahoo.comCentessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)February 5, 2024 | seekingalpha.comCentessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth PotentialFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Centessa Pharmaceuticals on Strong R&D Prospects and Market PotentialDecember 27, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive TherapeuticsSee More Headlines Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2021Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNTA CUSIPN/A CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$15.00 Low Stock Price Target$5.00 Potential Upside/Downside-11.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-216,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.03% Return on Assets-38.91% Debt Debt-to-Equity Ratio0.29 Current Ratio9.51 Quick Ratio9.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.55 per share Price / Book3.18Miscellaneous Outstanding Shares97,630,000Free Float86,363,000Market Cap$1.10 billion OptionableOptionable Beta1.37 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Saurabh Saha M.D. (Age 48)Ph.D., CEO & Director Comp: $957.67kDr. Gregory M. Weinhoff M.B.A. (Age 53)M.D., Principal Accounting Officer & CFO Comp: $655kDr. David M. Chao Ph.D. (Age 56)Chief Administrative Officer Comp: $655kMs. Tia L. Bush (Age 53)Chief Technology & Quality Officer Ms. Kristen K. Sheppard Esq.J.D., Senior Vice President of Investor Relations & Corporate CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 43)General Counsel, Chief Compliance Officer & Corporate Secretary Ms. Karen M. Anderson (Age 56)Chief People Officer Dr. Antoine Yver M.D. (Age 66)M.Sc., Executive VP & Chairman of Development Comp: $449.58kDr. Harris L. Rotman Ph.D.Senior Vice President of Regulatory AffairsDr. Patrick Yue M.D.Senior VP of Clinical Development & Innovative MedicinesMore ExecutivesKey Competitors89bioNASDAQ:ETNBVerve TherapeuticsNASDAQ:VERVZentalis PharmaceuticalsNASDAQ:ZNTLSage TherapeuticsNASDAQ:SAGEARS PharmaceuticalsNASDAQ:SPRYView All CompetitorsInsiders & InstitutionsKaren M AndersonSold 51,160 sharesTotal: $607,780.80 ($11.88/share)Goldman Sachs Group Inc.Bought 14,081 shares on 3/1/2024Ownership: 0.025%Quarry LPBought 6,000 shares on 2/20/2024Ownership: 0.006%Price T Rowe Associates Inc. MDSold 9,670 shares on 2/16/2024Ownership: 2.601%Price T Rowe Associates Inc. MDSold 9,670 shares on 2/15/2024Ownership: 2.601%View All Insider TransactionsView All Institutional Transactions CNTA Stock Analysis - Frequently Asked Questions Should I buy or sell Centessa Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CNTA shares. View CNTA analyst ratings or view top-rated stocks. What is Centessa Pharmaceuticals' stock price target for 2024? 7 equities research analysts have issued 1 year price targets for Centessa Pharmaceuticals' shares. Their CNTA share price targets range from $5.00 to $15.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests that the stock has a possible downside of 11.5%. View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts. How have CNTA shares performed in 2024? Centessa Pharmaceuticals' stock was trading at $7.96 at the beginning of the year. Since then, CNTA shares have increased by 42.0% and is now trading at $11.30. View the best growth stocks for 2024 here. When is Centessa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our CNTA earnings forecast. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals plc (NASDAQ:CNTA) issued its quarterly earnings data on Sunday, November, 14th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.10. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Centessa Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (8.99%), Price T Rowe Associates Inc. MD (2.60%), Price T Rowe Associates Inc. MD (2.60%), Octagon Capital Advisors LP (2.11%), Franklin Resources Inc. (1.14%) and Affinity Asset Advisors LLC (0.82%). Insiders that own company stock include (Bermuda) Ltd Gap, Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman and Tia L Bush. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNTA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesMost important medical advance in 100 yearsThe Oxford ClubThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.